Hepatomas are exquisitely sensitive to pharmacologic ascorbate (P-AscH-) by Zhang, Xuan et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.7150/thno.35378
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Zhang, X., Liu, T., Li, Z., Feng, Y., Corpe, C., Liu, S., ... Wang, J. (2019). Hepatomas are exquisitely sensitive to
pharmacologic ascorbate (P-AscH-). Theranostics, 9(26), 8109-8126. https://doi.org/10.7150/thno.35378
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 29. Jul. 2020
Theranostics 2019, Vol. 9, Issue 26 
 
 
http://www.thno.org 
8109 
Theranostics 
2019; 9(26): 8109-8126. doi: 10.7150/thno.35378 
Research Paper 
Hepatomas are exquisitely sensitive to pharmacologic 
ascorbate (P-AscH-) 
Xuan Zhang1#, Tiefu Liu1#, Zehuan Li2#, Yanling Feng1, Christopher Corpe3, Shanshan Liu1, Jingpu Zhang1, Xiaomeng 
He1, Feng Liu1, Li Xu1, Longqiang Shen1, Shun Li1, Qianlin Xia4, Xiuhua Peng1, Xiaohui Zhou1, Weiping Chen5, 
Xiaoyan Zhang1, Jianqing Xu1, Jin Wang1 
1. Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Jinshan District, Shanghai 201508, China;  
2. Department of General Surgery, Zhongshan Hospital, Fudan University, 200032, Shanghai, China;  
3. King's College London, London, Nutritional Science Department, 150 Stamford street, waterloo, London, SE19NH, United Kingdom;  
4. Department of Laboratory Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China; 
5. Genomics Core, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.  
# These authors contributed equally to this work 
 Corresponding author: Jin Wang, PhD. Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Jinshan 
District, Shanghai 201508, China; Ph: 86-21-57036495; Fax: 86-21-57247094 Email: wjincityu@yahoo.com 
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). 
See http://ivyspring.com/terms for full terms and conditions. 
Received: 2019.04.01; Accepted: 2019.09.08; Published: 2019.10.18 
Abstract 
Rationale: Ascorbate is an essential micronutrient known for redox functions at normal physiologic 
concentrations. In recent decades, pharmacological ascorbate has been found to selectively kill tumour 
cells. However, the dosing frequency of pharmacologic ascorbate in humans has not yet been defined. 
Methods: We determined that among five hepatic cell lines, Huh-7 cells were the most sensitive to 
ascorbate. The effects of high-dose ascorbate on hepatoma were therefore assessed using Huh-7 cells 
and xenograft tumour mouse model. 
Results: In Huh-7 cells, ascorbate induced a significant increase in the percentage of cells in the G0/G1 
phase, apoptosis and intracellular levels of ROS. High doses of ascorbate (4.0 pmol cell-1), but not low 
doses of ascorbate (1.0 pmol cell-1), also served as a pro-drug that killed hepatoma cells by altering 
mitochondrial respiration. Furthermore, in a Huh-7 cell xenograft tumour mouse model, intraperitoneal 
injection of ascorbate (4.0 g/kg/3 days) but not a lower dose of ascorbate (2.0 g/kg/3 days) significantly 
inhibited tumour growth. Gene array analysis of HCC tumour tissue from xenograft mice given IP 
ascorbate (4.0 g/kg/3 days) identified changes in the transcript levels of 192 genes/ncRNAs involved in 
insulin receptor signalling, metabolism and mitochondrial respiration. Consistent with the array data, 
gene expression levels of AGER, DGKK, ASB2, TCP10L2, Lnc-ALCAM-3, and Lnc-TGFBR2-1 were increased 
2.05-11.35 fold in HCC tumour tissue samples from mice treated with high-dose ascorbate, and IHC 
staining analysis also verified that AGER/RAGE and DGKK proteins were up-regulated, which implied 
that AGER/RAGE and DGKK activation might be related to oxidative stress, leading to hepatoma cell death. 
Conclusions: Our studies identified multiple mechanisms are responsible for the anti-tumour activity of 
ascorbate and suggest high doses of ascorbate with less frequency will act as a novel therapeutic agent for 
liver cancer in vivo. 
Key words: Ascorbate, vitamin C, cancer, hepatoma, ROS, mitochondrial respiration. 
Introduction 
Vitamin C, also known as ascorbic acid 
(L-ascorbic acid, Asc), is an essential micronutrient for 
humans acting as a cofactor for various biosynthetic 
enzymes, especially those involved in scavenging 
reactive oxygen species (ROS) [1, 2]. Asc is also a weak 
acid (pKa of 4.1 - 4.2) and at physiologic pH (7.4) it 
exists predominantly in the anionic form (AscH-). 
Over 50 years ago Cameron and Pauling suggested 
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Asc (or AscH-) could be a potential drug for the 
treatment of cancer [3, 4]. However, its efficacy was 
refuted by subsequent double-blind studies that failed 
to show improvements in the survival of patients 
receiving oral vitamin C compared to placebo [5, 6]. 
Several more recent studies have shown IV ascorbate 
was an effective anticancer treatment for solid 
tumours when compared with orally administered 
ascorbate [1, 7]. Preclinical and clinical studies in 
cholangiocarcinoma (CC) [8], colon cancer [9, 10], 
glioblastoma multiforme (GBM) [11], melanoma [12], 
non-small cell lung cancer (NSCLC) [11], ovarian 
cancer [13], pancreatic cancer [14], and sarcoma [15] 
have revealed pharmacologic levels of ascorbate 
achievable by IV but not oral administration 
selectively kills cancer cells but not normal cells. 
Pharmacologic ascorbate (P-AscH-) in vivo (> 1.0 mM) 
could be reached in patients by IV injection (at an 
average dose of 0.5 g/kg) to kill cancer cells, without 
side effects [1, 10, 16]. Thus, identification of tumour 
types that are exquisitely sensitive to high doses of 
ascorbate in preclinical models can advance clinical 
testing.  
The efficacy of vitamin C treatment could not be 
judged from clinical trials if using only oral dosing, 
and only high intravenous doses of vitamin C 
produced high plasma concentrations that might have 
antitumor activity, moreover pharmacokinetic data at 
high intravenous doses of vitamin C in cancer patients 
are sparse [17]. Dr. Levine noticed when 1.25 g of 
vitamin C was given intravenously; plasma 
concentrations were significantly higher than when 
the vitamin was given orally [18]. At extracellular 
concentrations > 1.0 mM vitamin C was toxic to some 
cancer cells, possibly because high concentrations of 
vitamin C act as a pro-drug for hydrogen peroxide 
formation in plasma [18, 19]. In addition, the 
elucidation of mechanisms of cancer-selective cell 
death induced by ascorbate may also provide insight 
into liver cancer therapy. Rouleau verified that the 
extracellular formation of H2O2 by high doses of 
ascorbate was a prerequisite for cancer cell death via 
increased cytosolic calcium, which in turn promoted 
mitochondrial calcium uptake and oxidative 
metabolism in cancer cells [20]. Current clinical 
evidence on the therapeutic effect of high-dose IV 
ascorbate is ambiguous. We proposed a hypothesis 
that extracellular H2O2 formation is a key mediator of 
cell death by pharmacologic ascorbate, and that H2O2 
can cause death by multiple, distinct mechanisms in 
the same cell type. Only high doses of ascorbate have 
been described to possess anticancer effects, but the 
potential mechanisms of action are unclear. 
Hepatocellular carcinoma (HCC) is the third 
most common cause of cancer-related mortality 
worldwide and is usually diagnosed at a late stage 
[21, 22]. Although alternative strategies with 
sorafenib, lenvatinib and regorafenib might improve 
survival in patients with advanced HCC, the only 
potentially curative treatment for HCC is tumour 
resection. Moreover, only approximately 15% of HCC 
patients are amenable to operative treatment, and the 
chance that treatment for HCC will be curative 
remains low [23, 24]. HCC is therefore a clinical 
problem in urgent need of novel and effective 
anticancer approaches. Because there is an abundance 
of iron in liver and pharmacologic ascorbate kills 
various cancer cells by producing extracellular 
hydrogen peroxide via Fenton chemistry [7, 25-27] 
involving redox-active labile iron, we hypothesized 
that hepatoma cells might be more sensitive to 
pharmacologic ascorbate. However, a difficulty of 
using pharmacologic ascorbate is dosing frequency 
intervals which to date have not been described [28].  
In this study we first investigated ascorbate- 
induced cytotoxicity towards Huh-7, HCCLM9, 
MHCC97L and LO2 cells and demonstrated that 
Huh-7 cells were the cells most sensitive to ascorbate 
and hydrogen peroxide via mitochondrial 
dysfunction. We further assessed the effects of 
P-AscH- on mice with HCC in vivo and found the 
tumour growth was significantly reduced after IP 
injection of ascorbate at 4.0 g/kg/3 days compared to 
the tumour growth in the PBS control group. Gene 
array analysis identified the upregulation of AGER, 
DGKK, ASB2, TCP10L2, Lnc-ALCAM-3, and 
Lnc-TGFBR2-1 which were validated by qPCR. 
Peroxide induced mitochondrial dysfunction in HCC 
was also detected leading to cell death. Thus, our 
dose-response studies of ascorbate in cells, a xenograft 
tumour mouse model and the two case studies using 
high dose ascorbate treated HCC patients identified a 
big theoretical advantage of ascorbate in cancer 
treatment via multiple mechanisms.  
Materials and Methods 
Cell lines and cell culture. Human hepatic cells 
(LO2, HepG2, MHCC97L, and HCCLM9 cells) were 
cultured in RPMI-1640 medium, and Huh-7 cells were 
maintained in DMEM (Dulbecco's Modified Eagle 
Medium, Thermo Fisher) supplemented with 10% 
foetal bovine serum (FBS, Biological Industries) and 
1% penicillin and streptomycin and cultured in a 
humidified atmosphere of 37℃ with 5% CO2. Human 
LO2 and Huh-7 cells were purchased from the cell 
bank of the Shanghai Institute of Biochemistry and 
Cell Biology (Shanghai, China). MHCC97L and 
HCCLM9 cells were derived from the same host cell 
line MHCC97L as described previously [29]. 
Cell viability and soft-agar assay. Human 
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hepatic cells were seeded on a 96-well plate (1.0 x 104 
cells/well). The ascorbate dose gradient was set as 4.0 
mM at the highest, with double dilution to 15.63 μM. 
Cells were incubated with ascorbate for 24 hrs, 
followed by removal of the ascorbate from the 
cultured medium. Then, 10 μL of 5 mg/mL MTT 
(Thiazolyl Blue Tetrazolium Bromide, Sigma) was 
added to each well for 4 hrs, and 150 μL DMSO was 
added to each well to dissolve the formazan. The 
relative absorbance (λ = 570 nm) for each well was 
detected in an ELx808™ Absorbance Microplate 
Reader (BioTek, Winooski, VT, USA). The LD50 was 
determined from the plots of the percentage viability 
vs. the dose of compound added as described 
previously [30]. For the soft-agar assay, the five 
hepatic cells (1.0 × 103) were exposed to ascorbate for 1 
hr then washed and re-suspended in RPMI 1640 
culture Medium (ThermoFisher Scientific, Waltham, 
MA) supplemented with 10% FBS (ThermoFisher 
Scientific) for 0.3% ultra-pure agarose (Sigma-Aldrich, 
St. Louis, MO). The suspension was then poured over 
3 mL of pre-solidified 0.6% agar base (Sigma-Aldrich) 
in 60 mm2 dishes, and the plates incubated at 37°C 
with 5% CO2 atmosphere saturation. Plates were 
incubated for 14-21 days at 37°C, 5% CO2, and the 
growth medium on top of the agarose layer replaced 
each week. After the growth period, cells were fixed 
with 70% ethanol and stained with Coomassie Blue. 
All the colonies were counted in the fields (n = 9) of 
view which were photographed using an inverted 
phase microscope (Olympus CKX4SF; Tokyo, Japan) 
at 40× magnification. The plating efficiency and 
surviving fraction were determined by the clonogenic 
survival fraction vs. dose of ascorbate.  
Cell cycle and apoptosis analysis by flow 
cytometry. Huh-7 cells (1 x 105 cells / 6 cm plate) were 
exposed to ascorbate 0-10 pmol cell-1 for 24 hrs. The 
treated cells were harvested and fixed overnight with 
70% ethanol at 4°C. The fixed cells were washed twice 
with cold PBS containing 0.1% Triton, suspended in 
20 µg/µL propidium iodide (PI), 200 μg/mL RNase 
and 0.1% Triton X-100, and incubated for 20 min in the 
dark at 37°C. Cell cycle distribution was determined 
by fluorescence-activated cell sorting analysis of 
PI-stained ethanol-fixed cells using a Guava EasyCyte 
(Guava Technologies, Hayward, CA). For apoptosis 
analysis, the cells were measured using the FITC 
Annexin V Apoptosis Detection Kit with PI (Cat#: 
640914, BioLegend Inc., San Diego, CA, USA) 
according to the manufacturer’s instructions. As 
mentioned above, Huh-7 cells (1 x 105 cells / 6 cm 
plate) were exposed to ascorbate and H2O2 for 24 hrs. 
Adherent Huh-7 cells were collected and washed with 
BioLegend's Cell Staining Buffer, then suspended in a 
mixture staining buffer comprised of 45 μL Annexin V 
binding buffer, 2.5 μL FITC-Annexing V, and 2.5 μL PI 
for 15 min in the dark at 37°C. Apoptosis was 
measured by a FACSCalibur flow cytometer (BD 
Biosciences, San Jose, CA, USA). Data were analysed 
by FlowJo™ version 7.6.3 software (TreeStar, 
Ashland, OR, USA) and R software. 
Mitochondrial respiration and glycolysis stress 
test. The dynamics of mitochondrial oxidative 
phosphorylation or glycolysis were respectively 
assessed by comparing oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR) 
using a Cell Mito Stress Test Kit (Cat#: 103015-100, 
Seahorse Bioscience Santa Clara, California, USA) or 
Glycolysis Stress Test Kit (Cat#: 103020-100, Seahorse 
Bioscience Santa Clara, California, USA) on an XFe-24 
Extracellular Flux Analyzer (Seahorse Bioscience) as 
described previously [31]. In brief, Huh-7 cells (5.0 x 
104 cells / well XFe-24 cell culture microplate) were 
grown in DMEM supplemented with 10% foetal 
bovine serum and treated for 1 h with or without 
ascorbate (1.0, 4.0, 8.0, or 10 pmol cell-1). Cells were 
then washed twice with basal assay medium and 
pre-incubated for 1 h in a CO2-free incubator in 500 
μL/well of assay medium containing 10 mM glucose, 
1.0 mM pyruvate and 2.0 mM L-glutamine. An XFe-24 
Sensor Cartridge containing 1.0 mL/well of Seahorse 
XFe Calibrant was preincubated overnight at 37°C in a 
non-CO2 incubator. For Mito Stress Test, ten-fold 
concentrated compounds in the kit of oligomycin 
(Complex V inhibitor), carbonyl cyanide-4 
(trifluoromethoxy) phenylhydrazone (FCCP, 
mitochondrial uncoupler), and a mixture of rotenone 
(complex I inhibitor) and antimycin A (complex III 
inhibitor) were loaded into the XFe-24 Sensor 
Cartridge to produce final concentrations of 1.0 μM, 
1.0 μM, 0.5 μM and 0.5 μM, respectively. For the 
Glycolysis stress test, ten-fold concentrations of 
compounds from the kit containing glucose (fuel for 
glycolysis), oligomycin (Complex V inhibitor) and 
2-Deoxy-D-Glucose (2-DG, competitive inhibitor of 
hexokinase) were loaded into the matched cartridge 
to produce final concentrations of 10 mM, 1.0 μM and 
50 mM, respectively. After a 30-min calibration of the 
XF sensor with the preincubated sensor cartridge, the 
cell plates were separately loaded into the analyser, 
and mitochondrial respiratory and glycolysis 
parameters were analysed under basal conditions 
followed by the sequential injection of the complex 
inhibitors oligomycin, FCCP. For the Mito stress test a 
mixture of rotenone and antimycin A was added, and 
for the Glycolysis stress test, glucose, oligomycin and 
2-DG were added. Moreover, in Mito stress test, ATP 
production was evaluated by the difference between 
the basal OCR and the OCR after oligomycin 
injection; spare respiratory capacity (SRC) was 
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determined as the difference between maximal and 
basal OCRs; whereas, in Glycolysis Stress Test, 
glycolysis was evaluated as the difference in ECAR 
before oligomycin injection and glucose injection; 
non-glycolytic acidification was determined as the last 
ECAR prior to glucose injection. Data were analysed 
using Seahorse Wave 2.4 Software (Seahorse 
Bioscience) and normalized with cell number or 
proteins (Pierce BCA Protein Assay Kit,Thermo Fisher 
Scientific) loaded in each well. Quadruplicates of each 
cell treatment were analysed. 
Extracellular ascorbate oxidation analysis. The 
five hepatic cells (5.0 x 104 cells / well XFe-24 cell 
culture microplate) were grown in DMEM 
supplemented with 10% foetal bovine serum 
overnight. The rate of oxygen consumption of the five 
hepatic cell lines upon addition of ascorbate (3.0 mM) 
to the complete culture mediums was determined 
using a XFe-24 Extracellular Flux Analyzer (Seahorse 
Bioscience). The OCR represents the rate of H2O2 
production. The accumulation of H2O2 is determined 
through the addition of catalase (250 units mL−1) 
(bovine liver, Sigma C-1345) as described previously 
[32]. 
Intracellular ATP analysis. Intracellular ATP 
levels in Huh-7 cell were measured using the ATP 
Assay Kit (Beyotime Biotechnology, Shanghai, China). 
Huh-7 cells (1 x 105 cells / well) were exposed to 
ascorbate for 1 hr in six-well plate and washed by 
PBS. Then, 200 μL of lysis buffer was added to lyse the 
cells. After centrifugation at 12,000 for 5 min, 100 μL 
of ATP assay reagent was added to initiate the 
luminescence reaction. After 10 min, 20 μL of the 
supernatants was added to the ATP assay reagent and 
luminescence was measured on a Lumat LB 9507 tube 
luminometer (Berthold Technologies GmbH & Co. 
KG, Bad Wildbad, Germany). ATP standard curves 
with concentrations between 0 and 1000 μM were 
generated for each experiment. The ATP 
concentration was determined from the 
corresponding standard curve and converted to an 
intracellular concentration using the cell 
number/well as counted on a hemocytometer and 
normalized using protein concentration/well (Pierce 
BCA Protein Assay Kit, Thermo Fisher Scientific). 
Intracellular reactive oxygen species (ROS) 
level detection. Dihydroethidium (DHE) was used to 
measure the intracellular level of ROS. Huh-7 cells (1 x 
105 cells / 6 cm plate) were incubated with 
concentrations of ascorbate (0 - 10 pmol Cell-1) for 1 hr, 
washed and then incubated with ascorbate-free 
medium for 5 hrs for ROS analysis. After treatment, 
the cells were washed twice with PBS and incubated 
with 2.0 μM DHE at 37℃ in the dark for 30 min. 
Stained cells were washed, resuspended in PBS, and 
analysed using a FACStar flow cytometer and FlowJo 
analytical software. 
Measurement of catalase activity. Catalase 
activity was measured in Huh-7, HepG2, HCCLM9, 
MHCC97L and LO2 cell lysates using a 
spectrophotometric-based assay kit (Beyotime 
Biotechnology, Shanghai, China). Briefly, cells (1.0 × 
106) were harvested in 5.0 mL PBS. Cells were counted 
with the hemacytometer, so a well-defined number of 
cells was used in the assay. After cell lysis and 
centrifugation at 12,000 rpm for 5 min, the 
supernatants and catalase assay buffer were added to 
yield H2O2. The decomposition of H2O2 was measured 
at 520 nm in an ELx808™ Absorbance Microplate 
Reader (BioTek, Winooski, VT, USA). 
Glucose uptake assay. Glucose uptake per cell 
was measured using the Glucose uptake cell-based 
assay kit (Cayman Chemical, Ann Arbor, MI, USA). 1 
x 105 cells / mL were grown in 2.0 mL culture 
medium in 6- well plates overnight, and were then 
treated with different ascorbate for 1 hr. After 
medium was removed, the cells were rinsed in PBS, 
and incubated at 37°C in 2 mL culture medium for 5 
hrs. The cells were then incubated in triplicate with 20 
µM 2-NBDG2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) 
amino]-2-deoxy-D-glucose (2-NBDG) at 37◦C for 20 
min in 5% CO2, and washed with FBS free DMEM 
medium with 4.5 g/L D-glucose for 5 min. Finally, the 
cells were washed twice with prechilled PBS and 100 
μL of cell lysis buffer added. After centrifugation at 
12,000 × g for 5 min at 4°C, fluorescence of aliquots 
from supernatants was measured by a fluorescence 
microplate assay [33]. At the same time, a standard 
curve was generated by measuring the fluorescence of 
2.5-50 μM 2-NBDG in lysis buffer. 
Xenograft tumour mouse model and 
bioluminescence imaging. All mice were handled in 
strict accordance with good animal practice and 
institutional guidelines using an animal protocol 
approved by the Institutional Animal Care and Use 
Committee of the Shanghai Public Health Clinical 
Center. For the xenograft tumour model, we 
developed Huh-7 cells bearing lentivirus-luciferase, 
which was further modified to stably express the 
firefly luciferase gene by lentivirus transfection to 
facilitate the in vivo monitoring of tumour 
development. These cells were cultured to 80% 
confluence, harvested by trypsinization, washed twice 
by PBS, resuspended to a final concentration of 2 x 106 
cells / 100 μL in sterile PBS, and injected 
subcutaneously into the right flank of 6-week-old 
male nude mice. When the tumour volume reached 25 
- 50 mm3, the nude mice with subcutaneous Huh-7 
cell tumours were randomly divided into three 
groups: two treatment groups given IP injections of 
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200 μL and 400 μL of Vitamin C respectively (Cat#: 
H310211486; 5 mL: 1g; Shanghai Harvest 
Pharmaceutical Co. Ltd.) (2.0 g/kg or 4.0 g/kg 
ascorbate) and a control group given an equivalent 
volume of normal saline (PBS) (7 mice in each group). 
The weight of the mice was measured every two days. 
Bioluminescence imaging analysis. Tumour 
growth was assessed by bioluminescence imaging. 
Before they were imaged, the mice in each group were 
anaesthetized with 3% sodium pentobarbital via 
intraperitoneal injection. Then, 50 mg/kg 
pentobarbital sodium was injected intraperitoneally 
into each mouse after anaesthesia; mice were then 
given an IP injection of 150 mg/kg D-luciferin, and 
the image was captured after 30 min. The 
anaesthetized mice were placed in the heated imaging 
platform of an IVIS-100/Spectrum optical imaging 
system (Xenogen / Caliper, Mountain View, CA). 
Signal intensity was quantified as the sum of all 
detected photons within the region of interest per 
second. Tumours were fixed with formaldehyde and 
histologically evaluated to verify the accuracy of the 
bioluminescence data. Acquired images were 
analysed by the Living Image 3.1 software 
(Xenogen/Caliper, Alameda, CA). Fluorescence 
contrast, defined as radiance, was quantified using 
identical size regions of interest. The mice were killed 
humanely after 6 weeks, and the tumour was 
harvested for RNA, protein and 
immunohistochemical (IHC) analysis.  
RNA extraction and purification, gene 
expression profiling and data analysis. Total RNA 
was extracted from each group of cells using Trizol 
reagent following the manufacturer’s instructions. 
RNA integrity and concentration were assessed using 
an Agilent Bioanalyzer 2100 (Agilent technologies, 
Santa Clara, CA, US) and Nano Drop ND-2000 
(Nanodrop). For gene expression profiling, 1.0 μg 
RNA was amplified and labelled by the Low Input 
Quick Amp Labelling Kit, One-Color (Agilent 
Technologies, Santa Clara, CA, US) for one-colour 
processing, following the manufacturer’s instructions. 
The method used T7 RNA Polymerase Blend, which 
simultaneously amplified the target material and 
incorporated Cy3-CTP. Labelled cRNA was purified 
by a RNeasy mini kit (QIAGEN, GmBH, Germany). 
Then, 600 ng Cy3-labelled cRNA was hybridized to 
the Agilent SurePrint G3 Human Gene Expression 
Microarray (8 x 60K) for 17 hrs, washed with the Gene 
Expression Wash Buffer Kit, and scanned by Agilent 
Microarray Scanner (Agilent Technologies, Santa 
Clara, CA, US), following the manufacturer’s 
instructions. Data were extracted with Feature 
Extraction software 10.7 (Agilent Technologies, Santa 
Clara, CA, US) and analysed by R software. Gene 
Ontology (GO) analysis and KEGG (Kyoto 
Encyclopedia of Genes and Genomes) were 
performed to construct meaningful annotation of 
differentially expressed genes in HCC tumor tissue 
from mice treated with IP injection of ascorbate [34]. 
Quantitative reverse transcription-polymerase 
chain reaction (qRT-PCR). Five micrograms of RNA 
were used for the RT reaction cDNA synthesis step. 
The qPCR reactions were performed by the ABI 
StepOne Cycler. SYBR® Premix Ex TaqTM Ⅱ was 
purchased from TAKARA. The cycling procedure was 
as follows: 94°C for 30 s, 60°C for 30 s (40 cycles). 
CDK4, CDK6, c-Myc, Casp3, AGER, DGKK, ASB2, 
TCP10L2, Lnc-ALCAM-3, and Lnc-TGFBR2-1 
expression was assayed in xenograft tumour mice by 
qRT-PCR and the primer sequences were listed in 
Table S1. The individual Ct of the target gene was 
obtained from three different samples in each group, 
standardized by the Ct of the internal reference 18S. 
The fold change in transcriptional level relative to the 
control group was standardized by the ΔΔCt method. 
Immunohistochemical staining. Immunohis-
tochemical (IHC) staining for DGKK (Cat#: ab103681, 
Abcam) and AGER/RAGE (A-9) (Cat#: sc-365154, 
Santa Cruz Biotechnology, Inc.) was performed in 18 
formalin-fixed, paraffin-embedded HCC mouse 
tumour tissue samples. The study was approved by 
the Shanghai Public Health Clinical Center 
institutional review boards. The DGKK and AGER 
staining results were independently evaluated by two 
expert pathologists (Feng Y and Li Z). 
Western blots. Protein samples were lysed in 
RIPA buffer supplemented with protease inhibitors. 
Thirty micrograms of total protein were loaded per 
lane separated on a 10% sodium dodecyl 
sulfate-polyacrylamide gel by electrophoresis, and 
proteins transferred onto nitrocellulose membranes. 
The membranes were blocked with 5% milk in PBST 
and then incubated with a rabbit anti-Glut1 (Cat#: 
D160433, BBI Solutions) or rabbit anti-Glut 3 (Cat#: 
D260435, BBI Solutions), rabbit anti-human Casp 3 
(Cat#: D220074, BBI Solutions.) or c-Myc rabbit 
polyclonal antibody (Cat#: YT0991, Immunoway) or 
HSP 90 (C45G5) rabbit mAb antibody (Cat#: 4877, Cell 
Signaling Technology) at 4 °C overnight. After 
washing with PBST, the blots were treated with a 
horseradish peroxidase (HRP) conjugated anti-rabbit 
IgG or anti-mouse antibody for 1 hr at room 
temperature. Detection of proteins was performed 
using enhanced chemiluminescence and 
autoradiography. 
Statistical Analysis. The data were presented as 
the means ± SD from three independent experiments 
and evaluated through t-tests. Values of p < 0.05 were 
considered statistically significant. The analyses were 
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performed by GraphPad Prism 5 software (GraphPad 
Software, San Diego, CA, USA). 
Results 
Ascorbate-induced cytotoxicity and cell cycle 
arrest in hepatic cells 
The MTT assay was used to detect the 
ascorbate-induced cytotoxicity in cancerous and 
non-cancerous hepatic cell lines. As demonstrated in 
Figure 1A-D, different liver cancer cells showed 
differential sensitivity to ascorbate (Figure 1A) and 
H2O2 (Figure 1B). The LD50 values of ascorbate on 
Huh-7, HCCLM9, HepG2 and MHCC97L cells were 
found to be 200 μM, 300 μM, 950 μM and 2000 μM, 
respectively, while the normal hepatocyte LO2 cells 
maintained 80% viability even at 4.0 mM ascorbate. At 
the same time, the LD50 values of H2O2 on HCCLM9, 
Huh-7, HepG2, MHCC97L and LO2 cells were found 
to be 10 μM, 55 μM, 200 μM, 320 μM and 450 μM, 
respectively. In the soft agar assay, P-AscH- moles per 
cell were used to specify dose [32]. Consistent with 
our MTT assay after one hour ascorbate treatment a 
differential sensitivity to ascorbate was detected in the 
five hepatic cell lines, Huh-7, HCCLM9, HepG2, 
MHCC97L, and LO2 (Figure 1C and Figure S1). 
Because Huh-7 cells had the lowest LD50 for 
ascorbate, we characterized these cells more 
extensively. Cell cycle changes induced by ascorbate 
were measured by PI staining (Figure 1D-F). 
Ascorbate at concentrations of 2.0 pmol cell-1 induced 
a significant increase (from 23.62% to 31.16%) in the 
percentage of cells in the G0/G1 phase and an even 
larger decrease (from 53.53% to 30.69%) in the S phase 
(Figure 1F) compared to no treatment (Figure 1D). 
qRT-PCR analysis showed that the expression of the 
cell cycle-related genes CDK4 and CDK6 in Huh-7 
cells were increased by the 2.0 pmol cell-1 Asc 
treatment (Figure 1G-H). Annexin V-FITC and PI 
staining was applied to detect apoptosis in Huh-7 
cells. As shown in Figure 1I-K, after treatment with 
ascorbate, apoptosis of Huh-7 cells occurred in a 
concentration-dependent manner. Compared with the 
control group, the group treated with 2.0 pmol cell-1 
ascorbate exhibited a significantly higher percentage 
of apoptotic cells (Figure 1K). 24 hrs after Asc 
treatment apoptosis induction occurred in 24% of 
treated cells compared to 1% in control cells. In 
addition, apoptosis-related genes c-Myc and Casp3 
(caspase-3) were analysed by qRT-PCR. As shown in 
Figure 1L-M, the expression of c-Myc and Casp3 
increased in a concentration-dependent manner. 
Immunoblot analysis also demonstrated that Casp3 
increased its expression when Huh-7 were treated 
with increased concentrations of ascorbate. c-Myc 
protein expression also increased after treatment with 
4.0 pmol cell-1 ascorbate but decreased with 10 pmol 
cell-1 ascorbate (Figure 1N). These findings are 
consistent with previous studies which showed 
oncogenic signals such as Ras and c-myc are involved 
in the process of hepatocarcinogenesis and regulate 
the expression of metabolic enzymes which induce 
cancer cell death by apoptosis [35-37].  
Because Asc oxidation can generate H2O2, which 
is cyctotoxic to cancer cell [32], we hypothesized that 
the sensitivity of hepatic cancer cells to ascorbate was 
due to their lower capacity to remove extracellular 
H2O2. An XFe-24 Extracellular Flux Analyzer was 
used to measure the amount of H2O2 in complete 
culture medium with five hepatic cells after 
dissolution of ascorbate (Figure 2A-C). The rate of 
oxygen consumption (OCR) upon addition of 
ascorbate to DMEM cell culture medium provides 
information on the productionof H2O2 [32, 38]. In our 
experimental setting in which 10,000 cells were 
treated with 3.0 mM Asc in 100 μL of DMEM medium. 
Addition of ascorbate to culture medium resulted in 
an increase in the background rate of oxygen 
consumption rate (Last rate measurement before 
ascorbate injection) - (Minimum rate measurement 
after ascorbate). The metabolic rates of oxygen 
consumption by Huh-7 and HCCLM9, MHCC97L, 
HepG2 and LO2 cells were 35.03, 30.03, 41.09, 48.74 
and 73.28 pmol min-1 cell−1, respectively (Figure 2B), 
which represents the rate of H2O2 production from the 
oxidation of ascorbate. Next, addition of catalase 
indicated an accumulation of H2O2 (Maximum rate 
measurement after catalase) - (last rate measurement 
after ascorbate) in the medium over the course of an 
experiment. The assay revealed that the amount of 
H2O2 in the presence of cells, especially LO2 (1.62 
pmol min-1 cell−1) and HCCLM9 cells (0.72 pmol min-1 
cell−1), was less than that in HepG2 (2.25 pmol min-1 
cell−1), Huh-7 (4.00 pmol min-1 cell−1) and MHCC97L 
(6.43 pmol min-1 cell−1) (Figure 2C). These findings 
indicate that ascorbate oxidation produces 
extracellular H2O2, the sensitivity of these hepatic cells 
to P-AscH- is possibly due to their lower capacity to 
remove extracellular H2O2. Indeed, the differential 
sensitivity to Asc across different cancer cells was also 
reflected by catalase activity. We measured 
intracellular catalase activity in Huh-7, HepG2, 
HCCLM9, MHCC97L and LO2 cell lysates. We 
verified the catalase activity of LO2 and HepG2 cells 
(0.075 Unites cell-1) were higher than that of Huh-7 
(0.045 Unites cell-1) and HCCLM9 (0.053 Unites cell-1) 
(Figure 2D), which was consistent with our results 
showing ascorbate oxidation and H2O2- induced 
cytotoxicity (Figure 1A-C). Our results demonstrated 
that extracellular ascorbate oxidation and intracellular 
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catalase levels could be corelated to the sensitivity to 
P-AscH- across different hepatic cells. However, we 
also noted that catalase activity in MHCC97L cells 
was less than that in other hepatic cells, which 
suggested other metabolic pathways might also be 
involved in hepatic cell sensitivity to P-AscH-.  
 
 
Figure 1. The effect of ascorbate and H2O2 on hepatic cells. Relative cytotoxicity of ascorbate (A, C) and H2O2 (B) on liver normal and cancer cells. Ascorbate induced 
G1 arrest (D-F) and apoptosis (I-K) in Huh-7 cells. qRT-PCR analysed CDK4 (G) and CDK6 (H), c-Myc (L), and Casp3 (M) gene expression in ascorbate-treated Huh-7 cells. 
Immunoblots analysis of c-Myc and Casp3 expression in ascorbate-treated Huh-7 cells (N). 
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Figure 2. Ascorbate was oxidized in medium generating a flux of H2O2 (A-C) and catalase activity varies across cancer cell lines (D). A, B) The rate of oxygen consumption upon 
the introduction ascorbate (3.0 mM) in medium; C) Addition of catalase leads to a return of oxygen, which indicates that H2O2 accumulated in the medium; D) Catalase activity 
assay. 
 
Ascorbate modifies the mitochondrial 
energetics of HCC cancer cells. 
We then hypothesized that ascorbate cytotoxicity 
on Huh-7 cells is mediated by altering mitochondrial 
respiration. To test this possibility, we compared the 
changes in oxygen consumption rate, spare 
respiratory capacity (SRC), and extracellular 
acidification rate (ECAR) in Huh-7 cells in response to 
different ascorbate doses. Mitochondrial parameters 
in Huh-7 cells were monitored using a Seahorse 
XFe-24 oxygen and proton flux analyser after 
treatment with 0 - 10 pmol cell-1 ascorbate for 1 hr. A 
biphasic phenotype of mitochondrial energetics was 
induced by the different ascorbate concentrations 
(Figure 3A). Comparing to the control cells, low-dose 
(1.0 pmol cell-1) ascorbate significantly increased in 
OCR at 25.41 pmol min-1 (p = 0.029) (Figure 3Bi) and 
ATP production (p = 0.027) (Figure 3Biv) but 
decreased in extramitochondrial OCR (p < 0.001) 
(Figure 3Biii), whereas mediate-dose (4.0 pmol cell-1) 
ascorbate depressed mitochondrial respiration with a 
significant reduction in ATP production (p = 0.016) 
(Figure 3Biv) and SRC (p = 0.004) (Figure 3Bv) but 
increased proton leakage (p = 0.022) (Figure 3Bii) and 
extramitochondrial OCR (p = 0.028) (Figure 3Biii); 
high doses (8.0 pmol cell-1 or 10 pmol cell-1) of 
ascorbate reduced mitochondrial respiration by 
minimizing OCR (p < 0.001) (Figure 3Biii), SRC (p = 
0.021) (Figure 3Bv) and ATP production (p < 0.001) 
(Figure 3Biv). ATP analysis of Huh-7 cells treated 
with ascorbate (0 - 10 pmol cell-1) also verified that 
P-AscH- decreased the intracellular concentration of 
ATP in Huh-7 in a dose-dependent manner (Figure 
3C). Surprisingly, in Huh-7 cells ascorbate appeared 
to have no effect on glycolysis; neither low- nor 
high-dose ascorbate significantly altered the 
extracellular acidification rate (ECAR) in Mito stress 
test (Figure 3Aii) and Glycolysis stress test (Figure 
4A). Noticeably, ascorbate could selectively kill KRAS 
mutant cancer cells by downregulating Glut1 
expression to affect glucose consumption, but had no 
significant effect on the glycolytic rate in KRAS cells 
or BRAF Wild type (WT) cells [35, 36], similar to our 
results of ECAR in Huh-7 cells treated with different 
P-AscH- which have demonstrated that the glycolysis 
(Figure 4 Bi) and extracellular acidification rate 
(Figure 4 Bii) and were not significantly difference in 
ECAR (all p > 0.05). Previous studies have shown 
there was a remarkably low K-Ras rate or no BRAF 
mutation in hepatocellular carcinoma cells [39, 40] 
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and the mutations of KRAS and BRAF were not 
present in Huh-7 cells (http://amp.pharm.mssm. 
edu/Harmonizome/gene_set/HUH7/CCLE+Cell+Li
ne+Gene+Mutation+Profiles), which might explain 
why glycolysis, as measured by our ECAR assay, was 
unaffected by P-AscH- in Huh-7 cells. As illustrated in 
Figure 4C, glucose uptake was reduced in Huh-7 cells 
treated with P-AscH- and the fluorescence intensity 
decreased gradually when the ascorbate 
concentration was gradually increased from 4.0 pmol 
cell-1 to 10 pmol cell-1 with respect to the cell controls 
without ascorbate. To determine whether the changes 
in glucose transport occurred at the level of protein 
expression, we analysed the expressions of Glut1 and 
Glut3. Immunblots revealed that the expression levels 
of Glut1 and Glut3 were decreased in Huh-7 cells 
treated with P-AscH-, when compared to controls 
without ascorbate (Figure 4D).  
 
 
Figure 3. Mitochondrial (Mito) respiration and ATP assay in Huh-7 cells treated with different doses of ascorbate (0 - 10 pmol cell-1). Ai) Mito stress test: 
OCR (oxygen consumption rate); Aii) ECAR (extracellular acidification rate); B) Mitochondrial respiration parameters analysis in Mito stress test including basal OCR (i), Proton 
leak (ii), Non-mitochondrial respiration (iii), ATP production (iv) and SRC (spare respiratory capacity) (v); C) Intracellular ATP levels in Huh-7 cell by ATP Assay Kit; One-way 
ANOVA p values are shown to determine the significance across different doses. The significance between CTRL and other time points was determined by subsequent unpaired 
t-tests. *p<0.05, **p<0.01, and ***p<0.005 
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Figure 4. Glycolysis assay, ROS production and glucose uptake analysis in Huh-7 cells treated with different doses of ascorbate (0 - 10 pmol cell-1). A) 
ECAR curve by Glycolysis stress test; B) Glycolysis parameters analysis in Glycolysis stress test including glycolysis capacity (i) and Non-glycolytic Acidification (ii); C) 
Fluorescence intensity changes of 2-NBDG in cells for glucose uptake analysis; D) Immunoblots analysis of Glut1 and Glut3 expression; E) ROS analysed in Huh-7 treated with 
P-AscH by DHE; One-way ANOVA p values are shown to determine the significance across different doses. The significance between CTRL and other time points was 
determined by subsequent unpaired t-tests. *p<0.05, **p<0.01, and ***p<0.005 
 
As integrated mitochondrial respiration is 
closely associated with the production of reactive 
oxygen species (ROS), modifications of OCR and/or 
mitochondrial coupling (proton leak) may change the 
dynamics of ROS generation. We thus examined the 
effect of ascorbate on intracellular superoxide 
production using the oxidation-sensitive fluorescent 
probe DHE. As shown in Figure 4E, after treatment 
with ascorbate, the intracellular superoxide 
production was dramatically increased in Huh-7 cells 
treated with 8.0 pmol ascorbate per cell (p = 0.012) in a 
concentration-dependent manner. Collectively, these 
data indicated that ascorbate alters the mitochondrial 
bioenergetics of Huh-7 cells in a dose-dependent 
manner. Low-dose ascorbate boosts and high-dose 
depresses oxidative phosphorylation, which implied 
that the dose-dependent effects of ascorbate on the 
activation/depression of oxidative pathway might be 
associated with ROS generation.  
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Figure 5. The effect of xenograft tumour mice treated with ascorbate. A-C) The growth and volume of xenograft tumours in mice treated with ascorbate were 
measured after 6 weeks by bioluminescence imaging: A) Control (PBS); B) Ascorbate at 2.0 g/kg/3 days; C) Ascorbate at 4.0 g/kg/3 days. D-F) Bioluminescence imaging analysis 
of the total fluorescence intensity in mice with xenograft tumours treated with ascorbate on Day 28 (D) and Day 35 (E) after IP injection of ascorbate; G) The weights of mice 
with xenograft tumours treated with ascorbate. 
 
Pharmacologic ascorbate inhibited HCC 
growth in a mouse model 
For the xenograft tumour mouse model in vivo 
studies, we chose Huh-7 cells because of their 
sensitivity to ascorbate. To determine if 
pharmacologic ascorbate inhibits HCC growth, we 
treated the xenograft tumour model of Huh-7 cells 
bearing lentivirus-luciferase with either PBS, 2.0 
g/kg/3 days and 4.0 g/kg/3 days of ascorbate, 
respectively. Tumour volumes were then measured 
after 5 weeks of treatment by bioluminescence 
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imaging. We found tumour growth was significantly 
reduced with IP injection of ascorbate at 4.0 g/kg/3 
days on Day 28 (Figure 5D) and Day 35 (Figure 5E) 
(compared to the tumour growth in the PBS control 
group (Figure 5F). Huh-7 tumour volume in mice 
treated with a higher dose of ascorbate (4.0 g/kg/3 
days IP) was decreased by 48.09% compared to the 
tumour volume in control mice (PBS) (p < 0.05). 
However, Huh-7 tumour volume in mice treated with 
IP injection of ascorbate at 2.0 g/kg/3 days was 
increased by 17.53% compared to the volume of 
control tumours (PBS) (p < 0.05) (Figure 5E-F). HCC 
mice given IP injection of ascorbate at 4.0 g/kg/3 days 
weighed significantly more than HCC mice given IP 
injection of ascorbate at 2.0 g/kg/3 days and their 
controls (PBS) (23.5 g vs. 22.6 g, respectively, p < 0.05; 
23.5 g vs. 22.1 g, respectively, p < 0.05) after 6 weeks. 
However, HCC mice given IP injection of ascorbate at 
2.0 g/kg/3 days weighed no significantly differently 
to their controls (PBS) (22.6 g vs. 22.1 g, respectively, p 
= 0.69) (Figure 5G).  
Gene expression profiling and pathway analysis 
of HCC tumour tissue from mice given IP 
injection of ascorbate at 4.0 g/kg/3 days 
To further corroborate the possible molecular 
mechanism of HCC treated with ascorbate, we 
analysed the genome-wide mRNA expression profiles 
in nine HCC tumour tissue samples from three mice 
treated with IP injection of ascorbate at 4.0 g/kg/3 
days, three mice treated with IP injection of ascorbate 
at 2.0 g/kg/3 days, and three control mice (only PBS, 
without ascorbate IP). Using a normal cut-off value 
greater than two-fold and a P value at or below 0.05, 
we identified changes in transcript levels of 1632 and 
1501 genes/ncRNAs in HCC tumour tissue from mice 
treated with IP injection of ascorbate at 4.0 g/kg/3 
days and 2.0 g/kg/3 days compared with expression 
in their controls, respectively (Data not shown). 
Subsequently, a Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) analysis was performed to 
determine the top 30 pathways of the differential 
mRNAs. Nineteen common pathways were identified 
in mouse HCC tumour tissue treated with IP injection 
of ascorbate at 4.0 g/kg/3 days and 2.0 g/kg/3 days, 
including Type II diabetes mellitus, Type I diabetes 
mellitus, TGF-beta signalling pathway, 
Staphylococcus aureus infection, Rheumatoid 
arthritis, Protein digestion and absorption, Prion 
diseases, NOD-like receptor signalling pathway, 
Malaria, Leishmaniasis, Intestinal immune network 
for IgA production, Fatty acid degradation, 
ECM-receptor interaction, Dilated cardiomyopathy, 
Complement and coagulation cascades, Antigen 
processing and presentation, Amoebiasis, Allograft 
rejection, and African trypanosomiasis (Figure 
S2A-B). In HCC tumour tissue from mice treated with 
IP injection of ascorbate at 2.0 g/kg/3 days compared 
with expression in their controls. Comparative 
analysis of the genome-wide mRNA expression 
profiles from HCC mouse HCC tumour tissue treated 
with IP injection of ascorbate at 4.0 g/kg/3 days and 
2.0 g/kg/3 days identified several metabolism and 
cell differentiation pathways, such as Vitamin 
digestion and absorption, Toll-like receptor signalling 
pathway, Renin-angiotensin system, Phagosome, 
Osteoclast differentiation, Maturity onset diabetes of 
the young, Linoleic acid metabolism, 
Glycosphingolipid biosynthesis, Glycosaminoglycan 
biosynthesis, Fat digestion and absorption, 
alpha-Linolenic acid metabolism were only included 
in the top 30 of GO analysis of mouse HCC tumour 
tissue treated with IP injection of ascorbate at 2.0 
g/kg/3 days (Figure S2A). Importantly, 192 
genes/ncRNAs were uniquely differentially 
expressed in HCC tumour tissue obtained from mice 
treated with IP injection of ascorbate at 4.0 g/kg/3 
days (not at 2.0 g/kg/3 days) when compared with 
expression in controls (Table S2). The microarray 
experiments revealed that the following genetic 
networks are altered in HCC treated with high-dose 
ascorbate: Hereditary Disorder, Nutritional Disease, 
Organismal Injury and Abnormalities; Cancer, 
Cellular Movement, Organismal Injury and 
Abnormalities; Haematological System Development 
and Function, Immune Cell Trafficking, Inflammatory 
Response; Connective Tissue Disorders, Organismal 
Injury and Abnormalities, Skeletal and Muscular 
Disorders; and Cell-To-Cell Signalling and Interaction, 
Behaviour, Digestive System Development and 
Function (Table 1). The genes deregulated in HCC 
treated with high-dose ascorbate belonged to five 
canonical signalling pathways that are frequently 
deregulated in cancer: Insulin Receptor Signalling, 
Dolichol and Dolichyl Phosphate Biosynthesis, 
UDP-N-acetyl-D-glucosamine Biosynthesis II, 
Ceramide Biosynthesis, and IL-3 Signalling Pathways 
(Table S3). Although seven genes (SCNN1A, 
PPP1R14C, BAD, INPP5D, DHDDS, FMO3, and 
SPTSSB) were represented in the signalling pathways, 
each of these seven genes is functionally involved in 
insulin receptor signalling and metabolism and has 
been implicated to mitochondrial respiration in the 
treatment of HCC with high-dose ascorbate [41, 42].  
AGER, DGKK, ASB2, TCP10L2, Lnc-ALCAM- 
3, and Lnc-TGFBR2-1 expression were altered 
in HCC tumour tissue from mice treated with 
high-dose ascorbate 
We validated the gene expression levels of 
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AGER, DGKK, ASB2, TCP10L2, Lnc-ALCAM-3, and 
Lnc-TGFBR2-1 in HCC tumour tissue samples from 
mice treated with high-dose ascorbate by qPCR. 
Consistent with array data, qRT-PCR analyses of 
AGER/RAGE (Advanced Glycosylation End-Product 
Specific Receptor; Receptor For Advanced 
Glycosylation End Products) and DGKK mRNA 
expression levels revealed a 5.08-fold (p = 0.020) and 
2.24-fold (p = 0.005) increase in AGER/RAGE and 
DGKK gene expression, respectively, in HCC tumour 
tissue samples from mice treated with high-dose 
ascorbate showed when compared to controls, and a 
11.35-fold (p < 0.001) and 2.47-fold (p = 0.001) increase 
in AGER/RAGE and DGKK gene expression, 
respectively, in HCC tumour tissue samples treated 
with low-dose ascorbate compared to controls 
respectively, when compared to controls (Figure 
6A-B). Lnc-ALCAM-3 and Lnc-TGFBR2-1) gene 
expression levels were increased in HCC tumour mice 
treated with high-dose Asc by (2.19 fold) (p = 0.035) 
(2.73 fold) (p < 0.001) respectively, when compared to 
controls, and by 2.05-fold (p = 0.111) and 3.61-fold (p < 
0.001) respectively in HCC tumour mice treated with 
low-dose ascorbate compared with controls were 
(Figure 6C-D). The repression of ASB2 and TCP10L2 
gene expression levels in HCC tumour mice treated 
with high-dose ascorbate compared to control was 
also verified. (Figure 6E-F). To further investigate the 
expression of AGER/RAGE and DGKK proteins in 
HCC tumour mice treated with high (4.0 g/kg/3d) 
and low-dose ascorbate (2.0 g/kg/3d), we performed 
immunohistochemical (IHC) staining of 18 tumour 
tissue samples (Figure 7) and observed weak 
membranous staining of AGER/RAGE in hepatoma 
cells and low-dose ascorbate tissue samples (Red 
arrow) (2.0 g/kg/3d IP), with the yellow arrow 
representing the area of necrosis (Figure 7C-E). The 
diffuse and strong membranous staining of 
AGER/RAGE in high-dose ascorbate samples (4.0 
g/kg/3 days IP) showed higher expression of the 
protein (Figure 7F). Weak cytoplasmic and nuclear 
staining of DGKK in hepatoma cells and in the 
low-dose ascorbate samples (2.0 g/kg/3d IP) is 
shown by the red arrows, whereas the yellow arrows 
represent the area of necrosis (Figure 7H). DGKK was 
strongly expressed in the cytoplasm of cancer cells 
and co-expressed in the nucleus and cytoplasm of few 
hepatoma cells in high-dose ascorbate samples (4.0 
g/kg/3 days IP) (Figure 7I). Taken together, stronger 
staining with both anti- AGER/RAGE and -DGKK 
antibodies was observed in HCC cancer cells treated 
with high-dose ascorbate (4.0 g/kg/3 days IP) (Figure 
7). 
Discussion  
Pharmacological ascorbate may represent an 
easily implementable drug as non-toxic adjuvant to 
conventional HCC treatments. To date there have 
been two case studies involving HCC patients and 
high dose IV ascorbate. One was a patient with a 
hepatocellular carcinoma with a remarkable response 
to high dose IV ascorbate that we received from 
clinicians in Malaysia (Dr. Raymond Ngeh and Dr. 
Robert Luk Clinical notes). The patient was a 
middle-aged woman with massive primary HCC. The 
cancer specialist suggested no further treatment as she 
will die in a few weeks. On her pre-treatment CT scan, 
the patient was given high dose IV vitamin C (1.5 - 2.0 
gram per kg body weight) and low dose 
chemotherapy which included 3 generic 
chemotherapy drugs at 1/3 usual dose 
(HiCLoChemo), PET/CT scan images of the patients 
after 4 cycles of HiCLoChemo treatment, compared 
with pre-treatment PET/CT scan were presented in 
the Figure S3. The HCC cancer is now in remission, 
and the patient remains otherwise healthy. In the 
second case report the patient presented with a 
metastatic disease to the left 8th rib and his medical 
oncologist determined that the patient was a 
candidate for standard of care chemotherapy with 
sorafenib along with 75 grams IV ascorbic acid 
administered three times per week. Before high dose 
IV vitamin C treatment, he had a left 8th rib 
metastasis (74 × 44 mm), along with a 2.8 × 2.2 cm 
ablation cavity from premetastatic treatment in the 
right lobe of the liver After 16-week cycles of 
ascorbate and sorafenib, his rib lesion was markedly 
smaller (43 × 28 mm), with no change in the liver 
function and no suggestion of additional metastasis. 
They also demonstrated that ascorbate could act 
synergistically with sorafenib in killing HepG2 cells 
involving the dysregulation of cellular calcium 
homeostasis [20]. The above two cases indicate that 
high dose IV ascorbate shows strong promise for the 
treatment of HCC in humans, and highlighted a 
plausible mechanism of the anti-tumour activity.  
 
Table 1. The top five networks of the 192 DEGs/ncRNAs in HCC mice treated with a high dose of ascorbate by IPA analysis. 
ID Analysis Molecules in Network Score Focus 
Molecules 
1 Hereditary Disorder, Nutritional 
Disease, Organismal Injury and 
ABCC2, ADGRF1, Akt, ANXA13, ASB2, CASP14, caspase, CHRND, CRLF1, DNMT3A, EDA, ENPP2, 
ERK, FMOD, FOXF2, GPR63, GPR75, GPR78, GPR176, HAMP, Histone h3, Insulin, Jnk, NFkB 
33 16 
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Abnormalities (complex), NKD1, NMUR1, P2RY10, Pkc(s), PPP1R14C, RNF112, S100A12, SLC52A1, Ubiquitin, 
USP2, Vegf 
2 Cancer, Cellular Movement, 
Organismal Injury and Abnormalities 
ACAN, B4GALNT1, CHGA, CLDN7, CPS1, CST2, DEFB121, EDN1, FAM81A, HSPA2, KCNJ1, 
KCNJ8, KRTAP10-3, MITF, MOV10 L1, NUPL2, PSMG2, PTOV1, PYGO2, RGPD4 (includes others), 
RNF175, SLC8A2, SMTNL2, SPATA8, STARD8, STX19, TBK1, TCP10/TCP10 L2, TMCC2, TMF1, 
TSFM, UBC, VEGFA, WFDC10B, YWHAZ 
31 15 
3 Haematological System Development 
and Function, Immune Cell 
Trafficking, Inflammatory Response 
AGER, AMPK, AQP4, BAD, CD3, EBI3, EFNB3, ERK1/2, FMO3, Gm-csf, Hsp70, IgG, IL12 (complex), 
Immunoglobulin, INPP5D, Interferon alpha, KLRG1, LDL, Mapk, P38 MAPK, p85 (pik3r), PI3K 
(complex), Pka catalytic subunit, Pro-inflammatory Cytokine, Ras, RET, SAA, SAG, SCNN1A, SPRR2C, 
SRC (family), TCR, Tgf beta, Tnf (family), VCAM1 
26 13 
4 Connective Tissue Disorders, 
Organismal Injury and 
Abnormalities, Skeletal and Muscular 
Disorders 
ACTA2, ALPL, ATXN2, C2orf40, CALCR, COL4A1, CTNNB1, DKK2, DKK3, DMKN, Ecm, F8A1 
(includes others), FAM173A, FOS, FOXF2, GABRA4, GABRD, HCST, Hd-neuronal intranuclear 
inclusions, KREMEN, KREMEN1, MT1A, MUC6, PAFAH1B2, RNA polymerase II, S100A11, SH3GL3, 
SPATA22, SRF, TGFB1, TMSB15A, TP53, VTRNA1-1, VTRNA1-2, VTRNA1-3 
26 13 
5 Cell-To-Cell Signalling and 
Interaction, Behaviour, Digestive 
System Development and Function 
ADCYAP1, AGER, Agtr1b, ARG1, Camk, CARTPT, CHGA, CHGB, CLCF1, CNKSR1, CREB1, CRTC1, 
DGKK, DLL3, DOK4, EBF3, GALR1, GFRA1, IRS, MAPK1, MAPK4, MC4R, MCAM, NPHS1, NRP1, 
ORM1, PRSS12, PTPRR, RFPL1/RFPL3, SCG2, SERPINA3, SGCD, SLC2A4, SORCS3, TACSTD2 
12 7 
*The genes (red) were up-regulated in HCC mice treated with a high dose of ascorbate and those labelled blue were down-regulated genes. 
 
 
Figure 6. Real-time PCR (qRT-PCR) analyses of AGER, DGKK, ASB2, TCP10L2. Lnc-ALCAM-3, and Lnc-TGFBR2-1 mRNA expression in xenograft tumour mice 
treated with ascorbate, which were evaluated through t-tests. A) ΔCt (AGER /18S); B) ΔCт (DGKK /18S); C) ΔCt (Lnc-ALCAM-3 /18S); D) ΔCt (Lnc-TGFBR2-1 /18S); E) ΔCт 
(ASB2 /18S); F) ΔCt (TCP10 L2 /18S). 
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Figure 7. Immunohistochemical (IHC) analysis of AGER (D-F) and DGKK (G-I) expression with HE staining (A-C) in xenograft tumour mice treated with 
ascorbate. A, D, G) Control (PBS); B, E, H) ascorbate (2.0 g/kg/3 days); C, F, I) ascorbate (4.0 g/kg/3 days). The staining of AGER and DGKK in hepatoma cells is shown with 
red arrows, whereas yellow arrows represent necrosis cells. 
 
Although most animals and plants can 
synthesize ascorbate through a sequence of 
enzyme-driven steps involving conversion of 
monosaccharides to ascorbate (Figure S4), some 
animals and human cannot synthesize ascorbate 
because of the lack of the functional L-gulonolactone 
oxidase (GULO) [43]. Importantly, ascorbate produces 
extracellular hydrogen peroxide involving 
redox-active labile iron and induces DNA damage 
and ATP depletion in CC, colon, NSCLC and GBM 
cancer cells [8, 10, 11, 44], which implies that cancer 
cells treated with high-dose ascorbate can utilize a 
metabolic pathway in the hypoxic environment of 
hepatoma. We therefore compared the changes in 
OCR, ECAR and SRC in Huh-7 cells in response to 
ascorbate treatment. Interestingly, low-dose (1.0 pmol 
cell-1) ascorbate promoted Huh-7 mitochondrial 
respiration with significant increases in OCR and ATP 
production but decreases in extramitochondrial OCR 
when compared to control untreated cells. These 
results are in accordance with previous studies where 
patient fibroblasts treated with ascorbate exhibited 
significantly higher ratios of complexes I-III and II-III 
in comparison to the same cell lines without ascorbate 
treatment [45]. High-dose (4.0 pmol cell-1) ascorbate 
however produced biphasic phenotype in 
mitochondrial energetics: mitochondrial respiration, 
ATP production and SRC were significantly reduced, 
but proton leakage, extramitochondrial OCR and 
intracellular ROS were increased. Due to essentiality 
of extracellular H2O2 and independent of 
mitochondria dysfunction, peroxide may trigger gene 
expression that leads to cell death; these data indicate 
high doses of ascorbate served as a pro-drug to kill 
hepatoma by altering mitochondrial respiration. 
Our main findings of the present study are that a 
high dose of ascorbate (4.0 g/kg/3 days) given by IP 
injection significantly repressed tumour growth, 
while a lower dose of ascorbate (2.0 g/kg/3 days) did 
not repress tumour growth of HCC. Given the 
pharmacokinetics of ascorbate, our results 
demonstrated that the pharmacological dose of 
ascorbate by IP injection was of critical importance 
with high doses of ascorbate inhibiting tumour 
growth whereas low doses act as a tumour growth 
factor. Our results of IP injection are in accordance 
with previous studies where the oral supplementation 
of ascorbate had no anticancer effect [5-7], and the 
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parenteral administration of high-dose ascorbate can 
significantly inhibit tumour growth in TLT 
(TREM-like transcript)-bearing mice [46]. However, 
the early phase research of ascorbate treatment was 
inappropriately performed, and the various 
parameters in these clinic studies (doses, routes of 
administration, optimal schedule) were not correctly 
defined or standardized, leading to mixed results and 
controversy [47]. Several papers have studied 
pharmacologic ascorbate in hepatoma using in vitro 
models [7, 20, 48]. In mice with the hepatoma 
parenteral administration of ascorbate either IV or IP 
1.0 g/kg of sodium ascorbate achieved pharmacologic 
concentrations of ascorbate in blood (>1.0 mM), 
whereas oral administration of the same dosage did 
not [7]. Only in parental administration was the 
growth rate of a murine hepatoma decreased, 
resulting in pharmacologic concentrations of 
ascorbate that exhibit interesting anticancer 
properties. A key advantage of IV ascorbate over 
conventional chemotherapeutic agent is its lack of 
toxicity. Because of these properties in vivo IV 
treatment would require less frequency. One studies 
where ascorbate frequency of one or two treatments 
with intravenous administration of ascorbate per 
week was similar to or less than ours [16]. Most 
animal tumours need daily or even twice daily 
treatment. If treatment is needed only every three 
days, this may mean that hepatoma in humans will be 
responsive to ascorbate at much less frequent dosing 
than is currently used for other tumours. The dosing 
frequency is a real clinical problem. If we have a 
cancer that requires less frequency, i.e. once weekly vs 
3 x weekly, this means the treatment is more likely to 
be tested in people and actually used: the special 
sensitivity of human hepatoma to IV ascorbate and 
the need for less frequent treatment is definitely an 
advantage. 
To determine the mechanistic basis of this 
phenotype, we analysed the gene expression profiles 
of HCC tumours from mice treated with IP injection 
of ascorbate at 4.0 g/kg/3 days using gene arrays and 
identified changes in transcript levels of 192 
genes/ESTs. The upregulation in AGER and DGKK 
gene expression was validated by qRT-PCR and IHC 
analysis. RAGE, a member of the immunoglobulin 
protein family, is a multiligand receptor able to bind 
to advanced glycation end products (AGEs), which 
are heterogeneous, reactive, and irreversibly 
crosslinking molecules formed primarily by the 
non-enzymatic reaction of sugars with proteins [49, 
50]. AGEs can induce the apoptosis of endothelial 
progenitor cells (EPCs) by activating RAGE. 
Dysregulation of the AGEs/RAGE axis in EPCs may 
promote atherosclerosis and the NADPH/ROS/JNK 
signalling axis may serve as a potential target of the 
clinical treatment of atherosclerosis [51, 52]. AGE and 
LPS increase IL-6 secretion depending on NF-κB 
activation and ROS production through RAGE [53]. 
RAGE stimulation also induces the generation of ROS 
mainly through the activity of NADPH oxidases. ROS 
accumulation has been linked to the formation of 
AGEs in various diabetic tissues [50]. When cells are 
unable to properly adapt to ROS generation, RAGE 
activation induces oxidative stress, leading to 
neuronal not cancer cell death [52]. DGKK 
(Diacylglycerol Kinase Kappa) was repressed in 
preputial tissues in carriers of the risk allele rs1934179 
[54, 55]. Treatment with H2O2 can result in the 
generation of diacylglycerol (DAG) and IP3, which 
could increase intracellular calcium and activate 
several forms of PKC, leading to Ras and Raf 
activation [56-58]. 
Pathway analysis of our gene array data 
identified five canonical signalling pathways 
dysregulated in cancer, namely, Insulin Receptor 
Signalling, Dolichol and Dolichyl Phosphate 
Biosynthesis, UDP-N-acetyl-D-glucosamine 
Biosynthesis II, Ceramide Biosynthesis, and IL-3 
Signalling pathways. Ascorbate attenuated upstream 
hepatic insulin action and affected hepatic insulin 
signalling by impairing the phosphorylation and 
activation of the insulin receptor and its subsequent 
substrates, which was found in rats [59]. Ascorbate 
suppresses the IL-3–induced phosphorylation of MAP 
kinase, which may modulate IL-3–mediated cytokine 
responses and therefore play a role in controlling 
inflammatory responses [60]. Ceramides can induce 
cell apoptosis by altering the cellular redox status to 
be responsible for signal transduction with ROS of 
many extracellular agents [61]. The 
ascorbate-mediated production of oxidative stress has 
been shown to retard the tumour growth of HCC, 
which remains the predominant mechanism behind 
the cellular effects of ascorbate [20, 62]. Ascorbate can 
induce the production of ROS, leading to oxidative 
stress and cell death, a death pathway that is 
interesting if we consider the multiple apoptotic 
defects usually exhibited by cancer cells. 
In summary, our in vitro studies have shown 
hepatic cancer cell death from pharmacologic levels of 
ascorbate are mediated by hydrogen peroxide, and 
our in vivo studies have shown IV ascorbate slows 
tumour growth via mitochondrial damage and 
multiple gene transcription changes. Our findings 
support the need for further detailed dose-response 
studies of ascorbate in an appropriate animal cancer 
model. The clinical efficacy of high-dose ascorbate in 
HCC treatment also needs to be explored. 
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